Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder

References

• Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology A report from the restless legs syndrome diagnosis and epidemiology workshop at the national institutes of health. Sleep Med. 2003;4(2):101–119. doi:10.1016/s1389-9457(03)00010-8
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Redline S, Baldwin CM, Resnick HE, Newman AB, Gottlieb DJ. Polysomnographic and health-related quality of life correlates of restless legs syndrome in the sleep heart health study. Sleep. 2009;32(6):772–778. doi:10.1093/sleep/32.6.772
   PubMed Web of Science ®Google Scholar
• Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286–1292. doi:10.1001/archinte.165.11.1286
   PubMedGoogle Scholar
• Pearson VE, Allen RP, Dean T, Gamaldo CE, Lesage SR, Earley CJ. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med. 2006;7(1):25–30. doi:10.1016/j.sleep.2005.05.006
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the sleep heart health study. Neurology. 2008;70(1):35–42. doi:10.1212/01.wnl.0000287072.93277.c9
   PubMed Web of Science ®Google Scholar
• Li Y, Wang W, Winkelman JW, Malhotra A, Ma J, Gao X. Prospective study of restless legs syndrome and mortality among men. Neurology. 2013;81(1):52–59. doi:10.1212/WNL.0b013e318297eee0
   PubMed Web of Science ®Google Scholar
• Lin CH, Sy HN, Chang HW, et al. Restless legs syndrome is associated with cardio/cerebrovascular events and mortality in end-stage renal disease. Eur J Neurol. 2015;22(1):142–149. doi:10.1111/ene.12545
   PubMed Web of Science ®Google Scholar
• Zhuang S, Na M, Winkelman JW, et al. Association of restless legs syndrome with risk of suicide and self-harm. JAMA Netw Open. 2019;2(8):e199966. doi:10.1001/jamanetworkopen.2019.9966
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141–1150. doi:10.1016/s1474-4422(13)70239-4
   PubMed Web of Science ®Google Scholar
• Park YM, Cho JH, Lim YS, Lee HJ, Kang SG, Kim L. The withdrawal from TDF therapy could induce transient RLS. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):419–420. doi:10.1016/j.pnpbp.2009.12.006
   PubMed Web of Science ®Google Scholar
• Scherbaum N, Stüper B, Bonnet U, Gastpar M. Transient restless legs-like syndrome as a complication of opiate withrawal. Pharmacopsychiatry. 2003;36(2):70–72. doi:10.1055/s-2003-39047
   PubMed Web of Science ®Google Scholar
• Mackie SE, McHugh RK, McDermott K, Griffin ML, Winkelman JW, Weiss RD. Prevalence of restless legs syndrome during detoxification from alcohol and opioids. J Subst Abuse Treat. 2017;73:35–39. doi:10.1016/j.jsat.2016.10.001
   PubMed Web of Science ®Google Scholar
• Ghosh A, Basu D. Restless legs syndrome in opioid dependent patients. Indian J Psychol Med. 2014;36(1):85–87. doi:10.4103/0253-7176.127262
   PubMedGoogle Scholar
• McCarter SJ, Labott JR, Mazumder MK, et al. Emergence of restless legs syndrome during opioid discontinuation. J Clin Sleep Med. 2023;19(4):741–748. doi:10.5664/jcsm.10436
   PubMed Web of Science ®Google Scholar
• Davis JP, Eddie D, Prindle J, et al. Sex differences in factors predicting post-treatment opioid use. Addiction. 2021;116(8):2116–2126. doi:10.1111/add.15396
   PubMed Web of Science ®Google Scholar
• Barta WD, Kurth ME, Stein MD, Tennen H, Kiene SM. Craving and self-efficacy in the first five weeks of methadone maintenance therapy: a daily process study. J Stud Alcohol Drugs. 2009;70(5):735–740. doi:10.15288/jsad.2009.70.735
   PubMed Web of Science ®Google Scholar
• Beswick T, Best D, Rees S, Bearn J, Gossop M, Strang J. Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments. Addict Biol. 2003;8(1):49–57. doi:10.1080/1355621031000069882
   PubMed Web of Science ®Google Scholar
• Dijkstra BA, Krabbe PF, De Jong CA, van der Staak CP. Prediction of withdrawal symptoms during opioid detoxification. J Opioid Manag Sep-Oct. 2008;4(5):311–319. doi:10.5055/jom.2008.0035
   PubMedGoogle Scholar
• Allen RP, Burchell BJ, MacDonald B, Hening WA, Earley CJ. Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. Sleep Med. 2009;10(10):1097–1100. doi:10.1016/j.sleep.2008.10.007
   PubMed Web of Science ®Google Scholar
• Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in Western Europe: prevalence and characteristics. Sleep Med. 2010;11(1):31–37. doi:10.1016/j.sleep.2009.03.007
   PubMed Web of Science ®Google Scholar
• Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5(3):237–246. doi:10.1016/j.sleep.2004.03.006
   PubMed Web of Science ®Google Scholar
• Winkelmann J, Prager M, Lieb R, et al. ”Anxietas tibiarum”. Depression and anxiety disorders in patients with restless legs syndrome. J Neurol. 2005;252(1):67–71. doi:10.1007/s00415-005-0604-7
   PubMed Web of Science ®Google Scholar
• AM D, Jain NK, Gupta M. Opioid use disorder. In: StatPearls. StatPearls Publishing; 2022.
   Google Scholar
• NIDA. Drug overdose death rates; 2023. Available from: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates. Accessed October 11, 2023.
   Google Scholar
• Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290–297. doi:10.15585/mmwr.mm6911a4
   PubMed Web of Science ®Google Scholar
• Higginbotham JA, Markovic T, Massaly N, Morón JA. Endogenous opioid systems alterations in pain and opioid use disorder. Front Syst Neurosci. 2022;16:1014768. doi:10.3389/fnsys.2022.1014768
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Wipper B, Zackon J. Long-term safety, dose stability, and efficacy of opioids for patients with restless legs syndrome in the national RLS opioid registry. Neurology. 2023;100(14):e1520–e1528. doi:10.1212/wnl.0000000000206855
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Purks J, Wipper B. Baseline and 1-year longitudinal data from the national restless legs syndrome opioid registry. Sleep. 2021;44(2):3.
   Web of Science ®Google Scholar
• Mahboub N, Rizk R, Karavetian M, de Vries N. Nutritional status and eating habits of people who use drugs and/or are undergoing treatment for recovery: a narrative review. Nutr Rev. 2021;79(6):627–635. doi:10.1093/nutrit/nuaa095
   PubMed Web of Science ®Google Scholar
• Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord. 2007;22(Suppl 18):S440–8. doi:10.1002/mds.21607
   PubMed Web of Science ®Google Scholar
• Ma MX, Huang Y, Adams LA, et al. Prevalence of restless legs syndrome in a tertiary cohort of ambulant patients with chronic liver disease. Intern Med J. 2018;48(3):347–350. doi:10.1111/imj.13719
   PubMed Web of Science ®Google Scholar
• Cho YW, Na GY, Lim JG, et al. Prevalence and clinical characteristics of restless legs syndrome in diabetic peripheral neuropathy: comparison with chronic osteoarthritis. Sleep Med. 2013;14(12):1387–1392. doi:10.1016/j.sleep.2013.09.013
   PubMed Web of Science ®Google Scholar
• Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology. 2009;72(11):955–960. doi:10.1212/01.wnl.0000336341.72621.db
   PubMed Web of Science ®Google Scholar
• Calviño J, Cigarrán S, Lopez LM, Martinez A, Sobrido MJ. Restless legs syndrome in non-dialysis renal patients: is it really that common? J Clin Sleep Med. 2015;11(1):57–60. doi:10.5664/jcsm.4366
   PubMed Web of Science ®Google Scholar
• Sperfeld AD, Unrath A, Kassubek J. Restless legs syndrome in hereditary spastic paraparesis. Eur Neurol. 2007;57(1):31–35. doi:10.1159/000097007
   PubMed Web of Science ®Google Scholar
• Fulda S, Allen RP, Earley CJ, et al. We need to do better: a systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. Sleep Med Rev. 2021;58:101461. doi:10.1016/j.smrv.2021.101461
   PubMed Web of Science ®Google Scholar
• Walters AS, LeBrocq C, Dhar A, et al. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121–132. doi:10.1016/s1389-9457(02)00258-7
   PubMed Web of Science ®Google Scholar
• Dreifuss JA, Griffin ML, Frost K, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend. 2013;131(1–2):112–118. doi:10.1016/j.drugalcdep.2012.12.010
   PubMed Web of Science ®Google Scholar
• Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146–150. doi:10.1370/afm.665
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Treatment of restless legs symptoms with pramipexole to improve the outcomes of protracted opioid withdrawal in OUD. Available from: https://clinicaltrials.gov/ct2/show/NCT04759703. Accessed October 11, 2023.
   Google Scholar